Literature DB >> 8782148

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.

J D Isaacs1, B L Hazleman, K Chakravarty, J W Grant, G Hale, H Waldmann.   

Abstract

A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional therapy. The mode of action of CAMPATH-1H and its relationship to clinical improvement are discussed.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8782148

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

2.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 3.  Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.

Authors:  G A Pangalis; M N Dimopoulou; M K Angelopoulou; C Tsekouras; T P Vassilakopoulos; G Vaiopoulos; M P Siakantaris
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 4.  Is biological therapy in systemic sclerosis the answer?

Authors:  Durga Prasanna Misra; Sakir Ahmed; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2020-01-20       Impact factor: 2.631

5.  Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

Authors:  E A Marsh; C L Hirst; J G Llewelyn; M D Cossburn; M M Reilly; A Krishnan; M Doran; A M Ryan; A J Coles; J L Jones; N P Robertson
Journal:  J Neurol       Date:  2010-01-06       Impact factor: 4.849

Review 6.  Alemtuzumab therapy for multiple sclerosis.

Authors:  Alasdair J Coles
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

7.  The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

Authors:  Alasdair J Coles; Amanda Cox; Emmanuelle Le Page; Joanne Jones; S Anand Trip; Jackie Deans; Shaun Seaman; David H Miller; Geoff Hale; Herman Waldmann; D Alastair Compston
Journal:  J Neurol       Date:  2005-07-27       Impact factor: 4.849

Review 8.  Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis.

Authors:  Ludivine Doridot; Mohamed Jeljeli; Charlotte Chêne; Frédéric Batteux
Journal:  Redox Biol       Date:  2019-01-25       Impact factor: 11.799
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.